Get in Touch

Enroll in a Study

Publication Library

Filter by Therapeutic Area | Clear Filters

Diabetes | Steatotic Liver Disease | Obesity | Services

Filter by Category | Clear Filters

Articles Icon

Articles

Posters Icon

Posters

Blog

Fact Sheet Icon

Fact Sheets

Textbooks Icon

Textbooks

image of Racing to Enroll, Failing to Retain: The Pitfalls of Competitive Enrollment in Clinical Trials

Racing to Enroll, Failing to Retain: The Pitfalls of Competitive Enrollment in Clinical Trials

image of GLY-200, an oral pharmacologic duodenal exclusion drug, resulted in positive effects on glucose, lipids and bodyweight in patients with type 2 diabetes: Results of a randomized, double-blind placebo-controlled trial

GLY-200, an oral pharmacologic duodenal exclusion drug, resulted in positive effects on glucose, lipids and bodyweight in patients with type 2 diabetes: Results of a randomized, double-blind placebo-controlled trial

image of Safety, Tolerability, and Pharmacokinetics of HM15275, a Novel GLP-1, GIP, and Glucagon Triple Receptor Agonist—Results from a Phase 1 Study

Safety, Tolerability, and Pharmacokinetics of HM15275, a Novel GLP-1, GIP, and Glucagon Triple Receptor Agonist—Results from a Phase 1 Study

image of Amplifying the Patient Voice—Understanding Motivations and Barriers in Type 2 Diabetes Clinical Trial Participation

Amplifying the Patient Voice—Understanding Motivations and Barriers in Type 2 Diabetes Clinical Trial Participation

image of Patient & Site Services: Redefining Patient Recruitment

Patient & Site Services: Redefining Patient Recruitment

image of A Randomized-Controlled, Double-Masked Cross-Over Study of a GPR119 Agonist on Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes

A Randomized-Controlled, Double-Masked Cross-Over Study of a GPR119 Agonist on Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes

image of Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors’ Perspective

Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors’ Perspective

image of Serological Biomarkers of the Extracellular Matrix Reflecting Fibroblast Activity and Endothelial Damage are Elevated in Patients at Risk of MASH With Significant Liver Stiffness

Serological Biomarkers of the Extracellular Matrix Reflecting Fibroblast Activity and Endothelial Damage are Elevated in Patients at Risk of MASH With Significant Liver Stiffness

(see more...)

image of A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin

A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin

image of Artificial Intelligence-assisted Digital Pathology For Non-alcoholic Steatohepatitis: Current Status And Future Directions

Artificial Intelligence-assisted Digital Pathology For Non-alcoholic Steatohepatitis: Current Status And Future Directions

image of Body weight independent effects of CT-868, a signalling biased dual GLP-1/GIP receptor modulator, on glucose homeostasis in overweight and obese adults with type 2 diabetes

Body weight independent effects of CT-868, a signalling biased dual GLP-1/GIP receptor modulator, on glucose homeostasis in overweight and obese adults with type 2 diabetes

image of Participant Feasibility: Direct Engagement With Patients to Impact MASH Trial Design and Site Selection

Participant Feasibility: Direct Engagement With Patients to Impact MASH Trial Design and Site Selection

image of CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

image of Double-Blind Crossover Study of Ultra-Rapid AT247 Compared with NovoLog and Fiasp during Continuous Subcutaneous Infusion (CSII) Assessed by a Hyperinsulinemic Euglycemic Clamp

Double-Blind Crossover Study of Ultra-Rapid AT247 Compared with NovoLog and Fiasp during Continuous Subcutaneous Infusion (CSII) Assessed by a Hyperinsulinemic Euglycemic Clamp

image of Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of The Novel Long-Acting Glucagon Analogue HM15136 In Overweight And Obese Patients With Co-Morbidities

Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of The Novel Long-Acting Glucagon Analogue HM15136 In Overweight And Obese Patients With Co-Morbidities

image of Weight-Independent Effects of CT-868, a Signaling Biased Dual GLP-1/GIP Receptor Modulator, on Glucose Homeostasis in Overweight and Obese Adults with Type 2 Diabetes

Weight-Independent Effects of CT-868, a Signaling Biased Dual GLP-1/GIP Receptor Modulator, on Glucose Homeostasis in Overweight and Obese Adults with Type 2 Diabetes

image of NASH PASS®: A Registry To Inform Study Design And Accelerate Patient Enrollment

NASH PASS®: A Registry To Inform Study Design And Accelerate Patient Enrollment

image of A randomized, single ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel insulin dimer

A randomized, single ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel insulin dimer

image of Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH

Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH

image of Community-Based Participatory Research Leads to Recruitment and Retention of NASH Subjects with Hispanic Background

Community-Based Participatory Research Leads to Recruitment and Retention of NASH Subjects with Hispanic Background

image of Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline

Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline

image of Automated Glucose Clamp Procedures for Diabetes Clinical Research

Automated Glucose Clamp Procedures for Diabetes Clinical Research

image of ProSciento Overview: Clinical R&D Services for Metabolic Diseases

ProSciento Overview: Clinical R&D Services for Metabolic Diseases

image of Hypoglycemic Clamp Studies

Hypoglycemic Clamp Studies

image of Hepatic De Novo Lipogenesis Assessment

Hepatic De Novo Lipogenesis Assessment

Fact Sheets, Glucose Clamp

Euglycemic Time-Action Profile Glucose Clamps

image of Hyperinsulinemic Euglycemic Insulin Sensitivity Clamp

Fact Sheets, Glucose Clamp

Hyperinsulinemic Euglycemic Insulin Sensitivity Clamp

image of Customized Programs for Clinical Development and Global Regulatory Services

Customized Programs for Clinical Development and Global Regulatory Services

image of ProSciento’s State-of-the-Art Clinical Research Center for Metabolic Studies

ProSciento’s State-of-the-Art Clinical Research Center for Metabolic Studies

image of Oral Glucose Tolerance and Mixed Meal Tolerance Tests

Oral Glucose Tolerance and Mixed Meal Tolerance Tests

image of Expediting NASH Clinical Trials and Biomarker Research: NASH PASS®, a Growing Clinical Research and Patient Registry Platform

Expediting NASH Clinical Trials and Biomarker Research: NASH PASS®, a Growing Clinical Research and Patient Registry Platform

image of Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease: A Focus on Early Phase Clinical Drug Development

Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease: A Focus on Early Phase Clinical Drug Development

Krentz, Andrew J., Christian Weyer and Marcus Hompesch, editors.

Springer International Publishing, 2019. DOI: 10.1007/978-3-030-11748-1.

image of 184 Insulin Sensitivity and Glucose Metabolism of Olanzapine and Combination Olanzapine and Samidorphan: A Phase 1 Exploratory Study in Healthy Volunteers

184 Insulin Sensitivity and Glucose Metabolism of Olanzapine and Combination Olanzapine and Samidorphan: A Phase 1 Exploratory Study in Healthy Volunteers

image of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of INS068 vs Insulin Degludec in Type 1 Diabetes at Steady State: a Phase I, Randomized, Double-blind, Cross-over Trial

Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of INS068 vs Insulin Degludec in Type 1 Diabetes at Steady State: a Phase I, Randomized, Double-blind, Cross-over Trial

image of A First in Human, Single Ascending Dose Study to Assess the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of AB101 in Subjects with Type 1 Diabetes

A First in Human, Single Ascending Dose Study to Assess the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of AB101 in Subjects with Type 1 Diabetes

image of DA-1241 a novel GPR119 agonist: Safety, tolerability, pharmacokinetics, and pharmacodynamics: Part 2 of multiple ascending dose study in type 2 diabetes patients

DA-1241 a novel GPR119 agonist: Safety, tolerability, pharmacokinetics, and pharmacodynamics: Part 2 of multiple ascending dose study in type 2 diabetes patients

image of DA-1241 a novel GPR119 agonist: Data on safety, tolerability and pharmacokinetics (PK), from part 1 of a phase 1b multiple ascending dose (MAD) study in healthy volunteers (HV)

DA-1241 a novel GPR119 agonist: Data on safety, tolerability and pharmacokinetics (PK), from part 1 of a phase 1b multiple ascending dose (MAD) study in healthy volunteers (HV)

image of Pharmacokinetic and Pharmacodynamic Bioequivalence between regular human insulin [rDNA origin] in 0.9% sodium chloride ready-to-use infusion 1U/mL and in 100U/mL concentrate diluted to 1U/mL in Healthy Males.

Pharmacokinetic and Pharmacodynamic Bioequivalence between regular human insulin [rDNA origin] in 0.9% sodium chloride ready-to-use infusion 1U/mL and in 100U/mL concentrate diluted to 1U/mL in Healthy Males.

image of TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial.

TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial.

image of Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study.

Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study.

image of Investigational Product (IP) Management for Metabolic Clinical Studies

Investigational Product (IP) Management for Metabolic Clinical Studies

image of Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients.

Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients.

image of Clinical Research Strategies to Drive Advances in Obesity Drug Development

Clinical Research Strategies to Drive Advances in Obesity Drug Development

image of Specialized Expertise to Drive Advances in Diabetes Drug and Device Development

Specialized Expertise to Drive Advances in Diabetes Drug and Device Development

image of Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non-alcoholic fatty liver disease: results from two early

Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non-alcoholic fatty liver disease: results from two early

image of Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin (U-500R) Administered via Continuous Subcutaneous Insulin Infusion (CSII) vs. Subcutaneous Injection (SCI) in Adults with Type 2 Diabetes and High Insulin Requirements

Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin (U-500R) Administered via Continuous Subcutaneous Insulin Infusion (CSII) vs. Subcutaneous Injection (SCI) in Adults with Type 2 Diabetes and High Insulin Requirements

image of Pharmacokinetic and Dose-Finding Studies on Efpeglenatide in Patients With Type 2 Diabetes

Pharmacokinetic and Dose-Finding Studies on Efpeglenatide in Patients With Type 2 Diabetes

image of Clinical Research Considerations for Biosimilar Insulins

Clinical Research Considerations for Biosimilar Insulins

image of NASH Patient Access and Screening Strategies or NASH PASS: An epidemiological, multicenter, prospective screening registry for adults with nonalcoholic steatohepatitis

NASH Patient Access and Screening Strategies or NASH PASS: An epidemiological, multicenter, prospective screening registry for adults with nonalcoholic steatohepatitis

image of Relationship Between Controlled Attenuation Parameter (CAP) and Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) in Subjects at High Risk for Nonalcoholic Fatty Liver Disease (NAFLD)

Relationship Between Controlled Attenuation Parameter (CAP) and Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) in Subjects at High Risk for Nonalcoholic Fatty Liver Disease (NAFLD)

image of NASH Clinical Drug Development – Imaging the Liver and Beyond

NASH Clinical Drug Development – Imaging the Liver and Beyond

image of Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption

Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption

image of Effect of Dawn Phenomenon on Glucose Infusion Rate During Glucose Clamp Studies In Subjects with Type 1 Diabetes

Effect of Dawn Phenomenon on Glucose Infusion Rate During Glucose Clamp Studies In Subjects with Type 1 Diabetes

image of Glucose Clamp Quality Parameters Among Study Populations

Glucose Clamp Quality Parameters Among Study Populations

image of Relationship between glycaemic control and weight loss with once-weekly efpeglenatide in uncontrolled type 2 diabetes: a subanalysis of EXCEED 203

Relationship between glycaemic control and weight loss with once-weekly efpeglenatide in uncontrolled type 2 diabetes: a subanalysis of EXCEED 203

image of Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205

Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205

image of Efficacy of efpeglenatide in patients with obesity and prediabetes: a subanalysis of the BALANCE 205 study

Efficacy of efpeglenatide in patients with obesity and prediabetes: a subanalysis of the BALANCE 205 study

image of Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study

Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study

image of Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide

Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide

image of Assessment of Glucose Fluxes Using Stable-Isotope Methods

Assessment of Glucose Fluxes Using Stable-Isotope Methods

image of Efficacy of Efpeglenatide in Patients with Obesity and Prediabetes: A Subanalysis of the BALANCE 205 Study

Efficacy of Efpeglenatide in Patients with Obesity and Prediabetes: A Subanalysis of the BALANCE 205 Study

image of NGM313, a Novel Activator of β-Klotho/FGFR1c, Improves Insulin Resistance and Reduces Hepatic Fat in Obese, Nondiabetic Subjects

NGM313, a Novel Activator of β-Klotho/FGFR1c, Improves Insulin Resistance and Reduces Hepatic Fat in Obese, Nondiabetic Subjects

image of A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese

A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese

image of Relationship between Glycemic Control and Weight Loss with Once-Weekly Efpeglenatide in Uncontrolled Type 2 Diabetes: A Subanalysis of EXCEED 203

Relationship between Glycemic Control and Weight Loss with Once-Weekly Efpeglenatide in Uncontrolled Type 2 Diabetes: A Subanalysis of EXCEED 203

image of Do Baseline Characteristics Impact Efficacy of Efpeglenatide QW in Uncontrolled Type 2 Diabetes?

Do Baseline Characteristics Impact Efficacy of Efpeglenatide QW in Uncontrolled Type 2 Diabetes?

image of Sotagliflozin Decreases Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption

Sotagliflozin Decreases Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption

image of Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes

Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes

image of Exploring the insulin secretory properties of the PGD2-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients.

Exploring the insulin secretory properties of the PGD2-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients.

image of In Vitro Studies to Evaluate the Receptor Kinetics of Efpeglenatide versus other Glucagon-Like Peptide-1 Receptor Agonists

In Vitro Studies to Evaluate the Receptor Kinetics of Efpeglenatide versus other Glucagon-Like Peptide-1 Receptor Agonists

image of Impact of praliciguat, a soluble guanylate cyclase stimulator, on blood pressure and metabolic parameters in patients with diabetes and hypertension

Impact of praliciguat, a soluble guanylate cyclase stimulator, on blood pressure and metabolic parameters in patients with diabetes and hypertension

image of MEDI4166, a novel antibody-peptide fusion molecule: multiple-ascending-dose study in patients with type 2 diabetes

MEDI4166, a novel antibody-peptide fusion molecule: multiple-ascending-dose study in patients with type 2 diabetes

image of The effect of efpeglenatide on lipid profiles and overall metabolism in patients with type 2 diabetes and obese patients without diabetes

The effect of efpeglenatide on lipid profiles and overall metabolism in patients with type 2 diabetes and obese patients without diabetes

image of Preclinical effects of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist, compared with liraglutide and dulaglutide

Preclinical effects of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist, compared with liraglutide and dulaglutide

image of Investigations into Tissue Distribution and Inhibition of Food Consumption with Efpeglenatide

Investigations into Tissue Distribution and Inhibition of Food Consumption with Efpeglenatide

image of Preclinical Effects of Efpeglenatide, a Long-Acting Glucagon-Like Peptide-1 Receptor Agonist, Compared with Liraglutide and Dulaglutide

Preclinical Effects of Efpeglenatide, a Long-Acting Glucagon-Like Peptide-1 Receptor Agonist, Compared with Liraglutide and Dulaglutide

image of Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.

Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.

image of Assessing the Cardiovascular Safety of Novel Diabetes and Obesity Medications –Implications for Early Phase Development

Assessing the Cardiovascular Safety of Novel Diabetes and Obesity Medications –Implications for Early Phase Development

image of Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development.

Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development.

Krentz, Andrew J., Lutz Heinemann and Marcus Hompesch, editors.

Springer-Verlag London, 2015. DOI: 10.1007/978-1-4471-4920-0.

image of Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals.

Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals.

Efpeglenatide, a Long-Acting Glucagon-Like Peptide-1 Receptor Agonist—Immunogenicity Profile Based on Preclinical and Clinical Studies

image of Fourteen-Day Study of Praliciguat, a Soluble Guanylate Cyclase Stimulator, in Patients with Diabetes and Hypertension

Fourteen-Day Study of Praliciguat, a Soluble Guanylate Cyclase Stimulator, in Patients with Diabetes and Hypertension

image of Exploring the Efficacy of Efpeglenatide, a Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA)—Evidence from Preclinical, Modeling, and Clinical Studies

Exploring the Efficacy of Efpeglenatide, a Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA)—Evidence from Preclinical, Modeling, and Clinical Studies

image of In Vitro Studies to Evaluate the Receptor Kinetics of Efpeglenatide vs. Other Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists

In Vitro Studies to Evaluate the Receptor Kinetics of Efpeglenatide vs. Other Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists

image of Investigations into Tissue Distribution and Inhibition of Food Consumption with Efpeglenatide

Investigations into Tissue Distribution and Inhibition of Food Consumption with Efpeglenatide

image of Application of a Non-Invasive Integrated Screening Algorithm to Improve Enrollment in NAFLD/NASH Clinical Trials

Application of a Non-Invasive Integrated Screening Algorithm to Improve Enrollment in NAFLD/NASH Clinical Trials

image of Importance of assessing the entire liver in MRI-PDFF studies of liver fat.

Importance of assessing the entire liver in MRI-PDFF studies of liver fat.

image of Pathophysiology of cardiovascular disease in diabetes mellitus.

Pathophysiology of cardiovascular disease in diabetes mellitus.

image of Cardiovascular outcome trials of diabetes and obesity drugs: implications for conditional approval and early phase clinical development.

Cardiovascular outcome trials of diabetes and obesity drugs: implications for conditional approval and early phase clinical development.

image of MEDI4166, a novel antibody (PCSK9)-peptide (GLP-1) fusion molecule: single-ascending-dose study in patients with type 2 diabetes

MEDI4166, a novel antibody (PCSK9)-peptide (GLP-1) fusion molecule: single-ascending-dose study in patients with type 2 diabetes

image of Weight loss unrelated to decrease in calorie intake after a single dose of a bispecific antibody to FGFR1/Klothoβ in obese subjects

Weight loss unrelated to decrease in calorie intake after a single dose of a bispecific antibody to FGFR1/Klothoβ in obese subjects

image of The novel glucagon receptor agonist SAR438544, first in human safety, pharmacokinetic and pharmacodynamic data from a study in healthy volunteers

The novel glucagon receptor agonist SAR438544, first in human safety, pharmacokinetic and pharmacodynamic data from a study in healthy volunteers

image of Leveraging a clinical phase Ib proof-of-concept study for the GPR40 agonist MK-8666 in patients with type 2 diabetes for model-informed phase II dose selection.

Leveraging a clinical phase Ib proof-of-concept study for the GPR40 agonist MK-8666 in patients with type 2 diabetes for model-informed phase II dose selection.

image of Significant Improvement of Blood Glucose Control in a High Risk Population of Type 1 Diabetes Using a Mobile Health App – A Retrospective Observational Study

Significant Improvement of Blood Glucose Control in a High Risk Population of Type 1 Diabetes Using a Mobile Health App – A Retrospective Observational Study

image of Significant improvement of blood glucose control in a high-risk population of type 1 diabetes using a mobile health app – a retrospective observational study.

Significant improvement of blood glucose control in a high-risk population of type 1 diabetes using a mobile health app – a retrospective observational study.

image of Graded Glucose Infusion for Assessment of β-Cell Function

Graded Glucose Infusion for Assessment of β-Cell Function

image of Introduction to Glucose Clamps: Automated Versus Manual Techniques

Introduction to Glucose Clamps: Automated Versus Manual Techniques

image of Glucose: archetypal biomarker in diabetes diagnosis, clinical management and research.

Glucose: archetypal biomarker in diabetes diagnosis, clinical management and research.

image of Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insulin.

Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insulin.

image of Glucodynamics of Long-Acting Basal Insulin Peglispro (BIL) Compared With Insulin Glargine at Steady State in Subjects with Type 1 Diabetes: substudy of a randomized crossover trial.

Glucodynamics of Long-Acting Basal Insulin Peglispro (BIL) Compared With Insulin Glargine at Steady State in Subjects with Type 1 Diabetes: substudy of a randomized crossover trial.

image of Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes.

Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes.

image of Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles

Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles

image of Considerations in biosimilar insulin device development

Considerations in biosimilar insulin device development

image of Biosimilar insulins: current and future perspectives

Biosimilar insulins: current and future perspectives

image of Biosimilar insulins: guidance for data interpretation by clinicians and users

Biosimilar insulins: guidance for data interpretation by clinicians and users

image of Anti-Obesity Pharmacotherapy: The Intercontinental Regulatory Divide

Anti-Obesity Pharmacotherapy: The Intercontinental Regulatory Divide

image of Steady state is reached within two to three days of once-daily administration of degludec, a basal insulin with an ultra-long duration of action

Steady state is reached within two to three days of once-daily administration of degludec, a basal insulin with an ultra-long duration of action

image of Subcutaneous Injection Depth Does Not Affect the Pharmacokinetics or Glucodynamics of Insulin Lispro in Normal Weight or Healthy Obese Subjects

Subcutaneous Injection Depth Does Not Affect the Pharmacokinetics or Glucodynamics of Insulin Lispro in Normal Weight or Healthy Obese Subjects

image of Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2

Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2

image of Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

image of Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial

image of Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes

Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes

image of Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes

Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes

image of Cardiovascular Safety of New Drugs for Diabetes: Getting the Balance Right?

Cardiovascular Safety of New Drugs for Diabetes: Getting the Balance Right?

image of Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensor

Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensor

image of Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies

Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies

image of Pharmacokinetic and Pharmacodynamic Responses of Insulin Degludec in African American, White, and Hispanic/Latino Patients With Type 2 Diabetes Mellitus

Pharmacokinetic and Pharmacodynamic Responses of Insulin Degludec in African American, White, and Hispanic/Latino Patients With Type 2 Diabetes Mellitus

image of Biosimilar Insulins: Basic Considerations

Biosimilar Insulins: Basic Considerations

image of Targeting hyperglycaemia with anti-obesity drugs: time for a paradigm shift

Targeting hyperglycaemia with anti-obesity drugs: time for a paradigm shift

image of Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes

Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes

image of First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

image of Insulin resistance: a risk marker for disease and disability in the older person

Insulin resistance: a risk marker for disease and disability in the older person

image of Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase

Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase

image of Developing new drugs for diabetes and cardiometabolic disorders: a changing paradigm

Developing new drugs for diabetes and cardiometabolic disorders: a changing paradigm

image of Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus

Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus

image of Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males

Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males

image of Type 2 diabetes or…? Still looking for a better name.

Type 2 diabetes or…? Still looking for a better name.

image of Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

image of Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase

Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase

image of Short-term metabolic effects of prednisone administration in healthy subjects

Short-term metabolic effects of prednisone administration in healthy subjects

image of Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects

Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects

image of Evaluation of a novel continuous glucose measurement device in patients with diabetes mellitus across the glycemic range

Evaluation of a novel continuous glucose measurement device in patients with diabetes mellitus across the glycemic range

image of Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers

Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers

image of Biosimilar Insulins: How Similar is Similar?

Biosimilar Insulins: How Similar is Similar?

image of Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin

Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin

image of Future Treatments for Type 2 Diabetes

Future Treatments for Type 2 Diabetes

image of Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection

Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection

image of Continuous glucose monitoring using a novel glucose/galactose binding protein: results of a 12-hour feasibility study with the becton dickinson glucose/galactose binding protein sensor

Continuous glucose monitoring using a novel glucose/galactose binding protein: results of a 12-hour feasibility study with the becton dickinson glucose/galactose binding protein sensor

image of Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase

Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase

image of Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction

Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction

menu